HSR19-107: Nivolumab for Newly Diagnosed Classical Hodgkin Lymphoma: Patient-Reported Outcomes From CheckMate 205 Cohort D

Authors:
Radhakrishnan Ramchandren University of Tennessee Knoxville, TN

Search for other papers by Radhakrishnan Ramchandren in
Current site
Google Scholar
PubMed
Close
 MD
,
Stephen M. Ansell Mayo Clinic, Rochester, MN

Search for other papers by Stephen M. Ansell in
Current site
Google Scholar
PubMed
Close
 MD
,
Philippe Armand Dana-Farber Cancer Institute, Boston, MA

Search for other papers by Philippe Armand in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Andreas Engert University Hospital of Cologne, Cologne, Germany

Search for other papers by Andreas Engert in
Current site
Google Scholar
PubMed
Close
 MD
,
Fiona Taylor Adelphi Values, Boston, MA

Search for other papers by Fiona Taylor in
Current site
Google Scholar
PubMed
Close
,
Kim Cocks Adelphi Values, Bollington, United Kingdom

Search for other papers by Kim Cocks in
Current site
Google Scholar
PubMed
Close
 PhD
,
Clara Chen Bristol-Myers Squibb, Princeton, NJ

Search for other papers by Clara Chen in
Current site
Google Scholar
PubMed
Close
,
Bryan Bennett Bristol-Myers Squibb, Princeton, NJ

Search for other papers by Bryan Bennett in
Current site
Google Scholar
PubMed
Close
,
Alejandro Moreno-Koehler Adelphi Values, Boston, MA

Search for other papers by Alejandro Moreno-Koehler in
Current site
Google Scholar
PubMed
Close
,
Adam Roeder Adelphi Values, Boston, MA

Search for other papers by Adam Roeder in
Current site
Google Scholar
PubMed
Close
,
Anne Sumbul Bristol-Myers Squibb, Princeton, NJ

Search for other papers by Anne Sumbul in
Current site
Google Scholar
PubMed
Close
 MS
,
Mariana Sacchi Bristol-Myers Squibb, Princeton, NJ

Search for other papers by Mariana Sacchi in
Current site
Google Scholar
PubMed
Close
, and
David Cella Northwestern University, Chicago, IL

Search for other papers by David Cella in
Current site
Google Scholar
PubMed
Close
Full access

Background: Patients (pts) with classical Hodgkin lymphoma (cHL) frequently experience reduced health-related quality of life (HRQoL) (Oerlemans et al, Ann Hematol 2011). Nivolumab, a fully human IgG4 anti-programmed death-1 (PD-1) immune checkpoint inhibitor monoclonal antibody, demonstrated efficacy and clinically meaningful improvement in pt-reported outcomes (PROs) in pts with relapsed/refractory cHL in cohorts A, B, and C of CheckMate 205 (NCT02181738) (Armand et al, J Clin Oncol 2018; Engert et al, ASH 2017). Nivolumab monotherapy followed by nivolumab + doxorubicin, vinblastine and dacarbazine (N-AVD) demonstrated an objective response rate of 84% in newly diagnosed cHL (cohort D of CheckMate 205; Ramchandren et al, EHA 2018). We present PROs in CheckMate 205 cohort D. Methods: Pts ≥18 years of age with untreated, advanced-stage cHL, with ECOG performance status (PS) of 0–1 received 4 doses of nivolumab monotherapy (240 mg IV Q2W) followed by N-AVD for 6 cycles (12 doses). Pts then entered the follow-up (FU) period. PROs were an exploratory endpoint, assessed using the EuroQol 5 Dimensions-3 level (EQ-5D-3L) and associated visual analog scale (EQ-VAS) in all treated pts who had both a baseline (monotherapy cycle 1) and post-baseline assessment. EQ-VAS ranges from 0–100, with higher scores indicating better HRQoL. In EQ-5D-3L, pts can report no, some, or extreme problems in each of 5 dimensions (mobility, self-care, activity, pain, and anxiety). Results: 51 pts were treated. At baseline, median age was 37 years, 63% were male, 59% had ECOG PS of 0. 49 pts (96%) completed baseline EQ-VAS. Mean EQ-VAS scores exceeded the mean baseline score at the end of monotherapy, after 2 combination cycles, at the end of therapy, and during follow-up (Table 1). The proportion of pts reporting some or extreme problems in EQ-5D-3L was numerically lower than or similar to baseline after monotherapy for all dimensions, but was numerically higher than baseline (dimensions of mobility and activity) after 2 combination cycles, and remained close to or numerically below baseline during follow-up (dimensions of self-care, activity, pain, and anxiety). Conclusions: Pt-reported HRQoL, as assessed by observed mean EQ-VAS scores, did not deteriorate from baseline during treatment with nivolumab followed by N-AVD. Proportions of pts reporting problems in individual EQ-5D-3L dimensions were generally similar to baseline during treatment and follow-up.

Background: Patients (pts) with classical Hodgkin lymphoma (cHL) frequently experience reduced health-related quality of life (HRQoL) (Oerlemans et al, Ann Hematol 2011). Nivolumab, a fully human IgG4 anti-programmed death-1 (PD-1) immune checkpoint inhibitor monoclonal antibody, demonstrated efficacy and clinically meaningful improvement in pt-reported outcomes (PROs) in pts with relapsed/refractory cHL in cohorts A, B, and C of CheckMate 205 (NCT02181738) (Armand et al, J Clin Oncol 2018; Engert et al, ASH 2017). Nivolumab monotherapy followed by nivolumab + doxorubicin, vinblastine and dacarbazine (N-AVD) demonstrated an objective response rate of 84% in newly diagnosed cHL (cohort D of CheckMate 205; Ramchandren et al, EHA 2018). We present PROs in CheckMate 205 cohort D. Methods: Pts ≥18 years of age with untreated, advanced-stage cHL, with ECOG performance status (PS) of 0–1 received 4 doses of nivolumab monotherapy (240 mg IV Q2W) followed by N-AVD for 6 cycles (12 doses). Pts then entered the follow-up (FU) period. PROs were an exploratory endpoint, assessed using the EuroQol 5 Dimensions-3 level (EQ-5D-3L) and associated visual analog scale (EQ-VAS) in all treated pts who had both a baseline (monotherapy cycle 1) and post-baseline assessment. EQ-VAS ranges from 0–100, with higher scores indicating better HRQoL. In EQ-5D-3L, pts can report no, some, or extreme problems in each of 5 dimensions (mobility, self-care, activity, pain, and anxiety). Results: 51 pts were treated. At baseline, median age was 37 years, 63% were male, 59% had ECOG PS of 0. 49 pts (96%) completed baseline EQ-VAS. Mean EQ-VAS scores exceeded the mean baseline score at the end of monotherapy, after 2 combination cycles, at the end of therapy, and during follow-up (Table 1). The proportion of pts reporting some or extreme problems in EQ-5D-3L was numerically lower than or similar to baseline after monotherapy for all dimensions, but was numerically higher than baseline (dimensions of mobility and activity) after 2 combination cycles, and remained close to or numerically below baseline during follow-up (dimensions of self-care, activity, pain, and anxiety). Conclusions: Pt-reported HRQoL, as assessed by observed mean EQ-VAS scores, did not deteriorate from baseline during treatment with nivolumab followed by N-AVD. Proportions of pts reporting problems in individual EQ-5D-3L dimensions were generally similar to baseline during treatment and follow-up.

T1

Corresponding Author: Radhakrishnan Ramchandren
  • Collapse
  • Expand